arrow_back Back to App

Drug Approval Changes: New Rules for Innovative Substances

This law changes how new drugs and biological products are defined and approved, focusing on the "active moiety" instead of the "active ingredient." This aims to standardize the approval process and may affect the availability of new therapies, potentially speeding up or slowing down the market introduction of certain drugs.
Key points
The definition of a "new chemical entity" in drug law has shifted from "active ingredient" to "active moiety," which may impact which drugs are considered innovative.
New rules for consulting advisory committees before approving certain drugs and biological products have been introduced, aiming to provide additional safety and efficacy evaluations.
The changes also affect drugs for rare pediatric diseases, which could influence their development and availability for patients.
article Official text account_balance Process page
Became Law
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_415
Sponsor: Sen. Cassidy, Bill [R-LA]
Process start date: 2021-02-24
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_415.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-02-24.

What are the main provisions?

Key points include:

  • The definition of a "new chemical entity" in drug law has shifted from "active ingredient" to "active moiety," which may impact which drugs are considered innovative.
  • New rules for consulting advisory committees before approving certain drugs and biological products have been introduced, aiming to provide additional safety and efficacy evaluations.
  • The changes also affect drugs for rare pediatric diseases, which could influence their development and availability for patients.
What is the specific legal status?

The current status is Became Law.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Cassidy, Bill [R-LA].

What is the latest detailed status?

The latest detailed status is: Became Public Law No: 117-9.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health